For a patient with moderate-to-severe chronic obstructive pulmonary disease, how do Breztri (budesonide/formoterol/glycopyrrolate) and Trimbow (beclometasone dipropionate/formoterol fumarate/glycopyrrolate) compare in terms of efficacy, dosing frequency, inhaler device type, and tolerability?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Breztri vs Trimbow for Moderate-to-Severe COPD

Both Breztri (budesonide/glycopyrrolate/formoterol) and Trimbow (beclometasone dipropionate/glycopyrrolate/formoterol) are effective single-inhaler triple therapies (SITT) for moderate-to-severe COPD with high exacerbation risk, and current evidence demonstrates comparable efficacy between these agents, making either an appropriate choice based on availability, cost, and patient-specific factors.

Guideline Framework

The 2023 Canadian Thoracic Society guideline strongly recommends SITT for patients with moderate-to-severe COPD at high risk of exacerbations (≥2 moderate or ≥1 severe exacerbation in the past year), citing proven superiority including significant reduction in mortality 1. Single-inhaler formulations are explicitly favored over multiple inhalers due to increased adherence and reduced technique errors 1.

Comparative Efficacy

Exacerbation Reduction

  • Breztri: Demonstrated significant reduction in moderate-to-severe exacerbations over 52 weeks in the ETHOS trial (8,588 patients), with proven benefits in patients with FEV1 <65% predicted and exacerbation history 2
  • Trimbow: The TRIBUTE trial showed 15% reduction in exacerbation rates versus dual bronchodilator therapy (rate ratio 0.848, p=0.043) over 52 weeks 3
  • Head-to-head comparison: A 2021 network meta-analysis found comparable efficacy between budesonide/glycopyrrolate/formoterol and beclometasone/glycopyrrolate/formoterol across all outcomes including exacerbations, lung function, symptoms, and quality of life at both 24 and 52 weeks 4

Lung Function

Both agents demonstrate similar improvements in FEV1:

  • Breztri showed consistent improvements in trough FEV1 (76-119 mL improvement over comparators at 24 weeks) 2
  • Trimbow demonstrated comparable lung function benefits in the TRINITY trial 5
  • The network meta-analysis confirmed no significant differences in lung function outcomes between the two 4

Dosing and Device Characteristics

Dosing Frequency

  • Both require twice-daily administration (BID dosing)
  • Breztri: 2 inhalations twice daily (budesonide 320 mcg/glycopyrrolate 18 mcg/formoterol 9.6 mcg per actuation) 2
  • Trimbow: 2 inhalations twice daily (beclometasone 87 mcg/formoterol 5 mcg/glycopyrrolate 9 mcg per actuation) 3

Inhaler Device

  • Breztri: Pressurized metered-dose inhaler (pMDI) using Aerosphere technology with co-suspension delivery 2, 6
  • Trimbow: Extrafine pMDI formulation 3, 5
  • Both are pMDI devices, which may be advantageous for patients unable to generate sufficient inspiratory flow for dry powder inhalers

Safety and Tolerability

The safety profiles are remarkably similar:

  • Pneumonia risk: Trimbow showed 4% incidence in both treatment arms versus dual therapy 3; Breztri demonstrated similar low pneumonia rates 2
  • Adverse events: Both had comparable overall adverse event rates (Breztri: 64-67%; Trimbow: 55-58%) 2, 3
  • The network meta-analysis confirmed comparable safety and tolerability between the two agents 4

Common Adverse Events (Both Agents)

  • Nasopharyngitis
  • Upper respiratory tract infections
  • Headache
  • Dysphonia (typical ICS effect)

Clinical Decision Algorithm

Choose either agent based on:

  1. Formulary availability and cost - Often the primary determinant
  2. Prior ICS exposure - If patient previously tolerated budesonide, favor Breztri; if beclometasone, favor Trimbow
  3. Device familiarity - Both are pMDIs, but specific device training may influence choice
  4. Onset considerations - Breztri demonstrated median onset within 5 minutes on Day 1 2, though both contain formoterol (rapid-acting LABA)

Key Clinical Caveats

  • Do not use either agent as rescue medication; patients require separate short-acting bronchodilator 1, 7
  • Monitor for ICS-related effects: Both carry pneumonia risk, though rates are low and similar between agents
  • Ensure proper inhaler technique: pMDI devices require coordination; consider spacer if technique is suboptimal
  • Confirm high exacerbation risk: Triple therapy is specifically indicated for patients with ≥2 moderate or ≥1 severe exacerbation in past year 1
  • Avoid in mild disease without exacerbations: LAMA/LABA dual therapy is preferred for low exacerbation risk 1, 7

The evidence strongly supports that therapeutic equivalence exists between these two SITT options 4, making the choice primarily dependent on practical considerations rather than efficacy differences.

References

Related Questions

Should Breztri (beclomethasone dipropionate/formoterol fumarate/glycopyrrolate) be taken daily as a maintenance medication for COPD patients?
How should I correctly use Breztri (budesonide/formoterol/glycopyrrolate) inhaler, including dosing, technique, storage, and missed‑dose handling?
In a 66-year-old patient with chronic obstructive pulmonary disease who is prescribed Symbicort (budesonide/formoterol), what additional therapy should be given for cough?
What is the best treatment option for stable Chronic Obstructive Pulmonary Disease (COPD), Breztri (budesonide, glycopyrrolate, and formoterol) or Breo (fluticasone furoate and vilanterol)?
Is Breztri (budesonide, glycopyrrolate, formoterol) appropriate for an adult patient with emphysema requiring maintenance therapy?
What angle of plantarflexion should be used when applying an equinus cast?
What abdominal pain is considered normal at 21 weeks gestation?
Do atheroma plaques shrink over time?
What is the recommended allopurinol dosing for a patient with severe chronic liver disease (advanced hepatic impairment)?
For acute severe hypertension, when is intravenous hydralazine preferred over nicardipine infusion, and when is nicardipine preferred?
How should I manage a pregnant patient on enoxaparin (Clexane) and low‑dose aspirin who presents with vaginal bleeding?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.